TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer

What is the purpose of this trial?

This study will examine the safety and effectiveness of oxaliplatin in combination with TAS-102 (TAS-OX) for treatment of patients with metastatic colorectal cancer whose cancer has progressed or recurred after FOLFOX chemotherapy.

Yale Cancer Center

Start Date: 08/19/2016

End Date: 07/31/2019

Last Updated: 02/22/2018

Study HIC#: 1605017852